TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT
No Thumbnail Available
Date
2022
Authors
Swoboda, R.
Labopin, M.
Giebel, S.
Schroeder, T.
Kroeger, N.
Arat, M.
Savani, B.
Spyridonidis, A.
Hamladji, R. M.
Potter, V.